Abstract
Methotrexate has become the agent of choice for rheumatoid arthritis that does not respond to nonsteroidal anti-inflammatory drugs. In appropriately selected patients and with diligent monitoring, methotrexate in low weekly doses is effective and has a much better safety profile than was originally perceived.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 351-359 |
| Number of pages | 9 |
| Journal | Cleveland Clinic journal of medicine |
| Volume | 62 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1995 |
ASJC Scopus subject areas
- General Medicine